Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy
This study has been withdrawn prior to enrollment.
Information provided by:
First received: July 16, 2007
Last updated: July 22, 2011
Last verified: July 2011
To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance|
Resource links provided by NLM:
Further study details as provided by Salix Pharmaceuticals:
Primary Outcome Measures:
- To characterize the pharmacodynamics of single oral doses of MOA-728 compared to a positive control of MOA-728 administered intravenously in subjects on stable methadone maintenance.
|Study Start Date:||July 2007|
|Estimated Study Completion Date:||December 2007|
|Estimated Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
Contacts and Locations